Gilead Sciences: Neoplasms trials

The registry lists 15 Neoplasms studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 11Phase 2 3Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Magrolimab in Patients With Solid TumorsTerminatedNCT04827576Phase 2Results posted
• Study of Magrolimab Combinations in Participants With Myeloid MalignanciesTerminatedNCT04778410Phase 2Results posted
• Study to Assess the Effects of GS-3583 in Participants With Advanced Solid TumorsTerminatedNCT04747470Phase 1Results posted
• Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid TumorsTerminatedNCT04049617Phase 1Results posted
• Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid TumorsTerminatedNCT03954704Phase 1Results posted
• Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological MalignanciesTerminatedNCT03248479Phase 1Results posted
• Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese AdultsTerminatedNCT03135028Phase 1Results posted
• Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820TerminatedNCT02739360Phase 4Results posted
• Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver FunctionCompletedNCT02521376Phase 1Results posted
• Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell MalignanciesTerminatedNCT02457598Phase 1Results posted
• Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell MalignanciesCompletedNCT02457559Phase 1Results posted
• Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With IdelalisibTerminatedNCT03701438
• A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid MalignanciesCompletedNCT01705847Phase 1
• First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid TumorsCompletedNCT01323933Phase 1
• Safety Study of hMN14 to Treat Either Colorectal or Breast CancerCompletedNCT00041652Phase 1/2